ライフサイエンスコーパス: pegylated liposomal doxorubicin

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 benefits and toxicity outcomes also favored pegylated-liposomal doxorubicin.

2 ohort of patients who were then treated with pegylated-liposomal doxorubicin.

3 oup) received doxorubicin, epirubicin or non-pegylated liposomal-doxorubicin (10 mg/kg) and cardiac f

4 herapy were treated for six 3-week cycles of pegylated liposomal doxorubicin (20 mg/m(2)) plus interl

5 -KS were randomly assigned to receive either pegylated-liposomal doxorubicin (20 mg/m2) or the combin

6 Patients received pegylated liposomal doxorubicin 24 mg/m2 intravenously o

7 lenalidomide 25 mg, bortezomib 1.3 mg/m(2), pegylated liposomal doxorubicin 30 mg/m(2), and dexameth

8 T) and 2 lines of conventional chemotherapy (pegylated liposomal doxorubicin and docetaxel) was treat

9 luated combination lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone (RVDD

10 evidence for reduced cardiac toxicity of non-pegylated-liposomal doxorubicin characterized by attenua

11 ge (n = 102) received 4 cycles of bortezomib-pegylated liposomal doxorubicin-dexamethasone, tandem me

12 also enhanced the efficacy of i.v. injected pegylated liposomal doxorubicin (Doxil).

13 Patients received 20 mg/m2 pegylated-liposomal doxorubicin (Doxil; Sequus Pharmaceu

14 studied standard agents with rituximab plus pegylated liposomal doxorubicin (DR-COP) in an attempt t

15 e; these drugs include topotecan, etoposide, pegylated liposomal doxorubicin, epirubicin, gemcitabine

16 In HL-1 cells, non-pegylated liposomal-doxorubicin generated significantly

17 etermine the clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemc

18 Pegylated liposomal doxorubicin in combination with gemc

19 Pegylated liposomal doxorubicin is an effective treatmen

20 Pegylated-liposomal doxorubicin is more effective and le

21 Pegylated-liposomal doxorubicin offers a new alternative

22 Among 133 patients randomized to receive pegylated-liposomal doxorubicin, one achieved a complete

23 pegol versus one of the approved drugs (eg, pegylated liposomal doxorubicin or topotecan) in platinu

24 d dose-limiting toxicities of bortezomib and pegylated liposomal doxorubicin (PegLD).

25 II trial evaluated vintafolide combined with pegylated liposomal doxorubicin (PLD) compared with PLD

26 We have investigated pegylated liposomal doxorubicin (PLD) in a clearly defin

27 icacy and safety of patupilone with those of pegylated liposomal doxorubicin (PLD) in patients with p

28 red anticancer agents 4-hydroxytamoxifen and pegylated liposomal doxorubicin (PLD) in the prevention

29 parative efficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient po

30 Currently, pegylated liposomal doxorubicin (PLD) is a standard of c

31 the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib wi

32 a multicenter phase III study that compared pegylated liposomal doxorubicin (PLD) to the BV combinat

33 Since pegylated liposomal doxorubicin (PLD) was the most preva

34 the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD a

35 el, phase II trial evaluated the bortezomib, pegylated liposomal doxorubicin (PLD), and dexamethasone

36 In the healthy mouse, non-pegylated liposomal doxorubicin showed a minimal and non

37 After investigators selected chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel, or t

38 acy and toxicities of a new form of therapy, pegylated-liposomal doxorubicin, with standard combinati

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。